Regenxbio Inc (NASDAQ:RGNX) shares shot up 5.6% during trading on Friday . The stock traded as high as $58.07 and last traded at $57.52. 572,932 shares were traded during mid-day trading, an increase of 5% from the average session volume of 544,179 shares. The stock had previously closed at $54.49.

Several research firms have recently commented on RGNX. Zacks Investment Research downgraded Regenxbio from a “buy” rating to a “hold” rating in a report on Saturday, February 23rd. BidaskClub upgraded Regenxbio from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 13th. Evercore ISI upgraded Regenxbio from an “in-line” rating to an “outperform” rating and set a $51.25 price target on the stock in a report on Monday, February 25th. ValuEngine downgraded Regenxbio from a “hold” rating to a “sell” rating in a report on Friday, December 21st. Finally, Barclays boosted their price target on Regenxbio from $83.00 to $88.00 and gave the company an “overweight” rating in a report on Tuesday, December 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $77.97.

The firm has a market cap of $2.09 billion, a PE ratio of 24.17 and a beta of 0.46. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.01.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.43. Regenxbio had a return on equity of 22.33% and a net margin of 45.74%. On average, analysts forecast that Regenxbio Inc will post -3.23 earnings per share for the current year.

In other Regenxbio news, SVP Curran Simpson sold 43,832 shares of Regenxbio stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $50.08, for a total transaction of $2,195,106.56. Following the sale, the senior vice president now directly owns 47,950 shares of the company’s stock, valued at approximately $2,401,336. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $47.29, for a total value of $709,350.00. Following the sale, the chief executive officer now directly owns 261,000 shares in the company, valued at $12,342,690. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 109,700 shares of company stock worth $5,319,057. Insiders own 16.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Berman Capital Advisors LLC bought a new stake in Regenxbio during the 4th quarter valued at approximately $33,000. NumerixS Investment Technologies Inc bought a new stake in Regenxbio during the 4th quarter valued at approximately $50,000. Riverhead Capital Management LLC boosted its position in Regenxbio by 137.5% during the 3rd quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 1,100 shares in the last quarter. LS Investment Advisors LLC boosted its position in shares of Regenxbio by 63.1% in the 4th quarter. LS Investment Advisors LLC now owns 2,260 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 874 shares in the last quarter. Finally, Meeder Asset Management Inc. boosted its position in shares of Regenxbio by 31.7% in the 4th quarter. Meeder Asset Management Inc. now owns 2,578 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 621 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece of content was originally published by Marea Informative and is the property of of Marea Informative. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.mareainformativa.com/news/2019/03/17/regenxbio-rgnx-shares-up-5-6.html.

About Regenxbio (NASDAQ:RGNX)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Article: How to calculate the intrinsic value of a stock

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.